Cargando…

Targeting Heat Shock Protein 90 for the Treatment of Malignant Pheochromocytoma

Metastatic pheochromocytoma represents one of the major clinical challenges in the field of neuroendocrine oncology. Recent molecular characterization of pheochromocytoma suggests new treatment options with targeted therapies. In this study we investigated the 90 kDa heat shock protein (Hsp90) as a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giubellino, Alessio, Sourbier, Carole, Lee, Min-Jung, Scroggins, Brad, Bullova, Petra, Landau, Michael, Ying, Weiwen, Neckers, Len, Trepel, Jane B., Pacak, Karel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573066/ https://www.ncbi.nlm.nih.gov/pubmed/23457505 http://dx.doi.org/10.1371/journal.pone.0056083

Ejemplares similares

High-Throughput Screening for the Identification of New Therapeutic Options for Metastatic Pheochromocytoma and Paraganglioma
por: Giubellino, Alessio, et al.
Publicado: (2014)

Hypoxia potentiates the cytotoxic effect of piperlongumine in pheochromocytoma models
por: Bullova, Petra, et al.
Publicado: (2016)

Bortezomib Alone and in Combination With Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death In Vitro and in Female Nude Mice
por: Bullova, Petra, et al.
Publicado: (2017)

Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics
por: Li, Qingdi Quentin, et al.
Publicado: (2017)

Post-translational modification and conformational state of Heat Shock Protein 90 differentially affect binding of chemically diverse small molecule inhibitors
por: Beebe, Kristin, et al.
Publicado: (2013)

Casein kinase 2 phosphorylation of Hsp90 threonine 22 modulates chaperone function and drug sensitivity
por: Mollapour, Mehdi, et al.
Publicado: (2011)

Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway
por: Pang, Ying, et al.
Publicado: (2017)

Pheochromocytoma (PHEO) and Paraganglioma (PGL)
por: Pacak, Karel, et al.
Publicado: (2019)

Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants
por: Prince, Thomas L., et al.
Publicado: (2015)

Plasma HSP90α and liver cancer: a potential biomarker?
por: Sourbier, Carole
Publicado: (2017)

New insights on the pathogenesis of paraganglioma and pheochromocytoma
por: Kantorovich, Vitaly, et al.
Publicado: (2018)

Tonantzitlolone cytotoxicity toward renal cancer cells is PKCθ- and HSF1-dependent
por: Sourbier, Carole, et al.
Publicado: (2015)

Cytocidal Activities of Topoisomerase 1 Inhibitors and 5-Azacytidine against Pheochromocytoma/Paraganglioma Cells in Primary Human Tumor Cultures and Mouse Cell Lines
por: Powers, James F., et al.
Publicado: (2014)

HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation
por: Kijima, Toshiki, et al.
Publicado: (2018)

External Beam Radiation Therapy in Treatment of Malignant Pheochromocytoma and Paraganglioma
por: Vogel, Jennifer, et al.
Publicado: (2014)

Pheochromocytoma and Paraganglioma: Current Functional and Future Molecular Imaging
por: Blanchet, Elise M., et al.
Publicado: (2012)

Mitochondrial Topoisomerase I is Critical for Mitochondrial Integrity and Cellular Energy Metabolism
por: Douarre, Céline, et al.
Publicado: (2012)

Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma
por: Ilanchezhian, Maran, et al.
Publicado: (2020)

Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging
por: Alrezk, Rami, et al.
Publicado: (2018)

Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies
por: Pang, Ying, et al.
Publicado: (2019)

Murine Models and Cell Lines for the Investigation of Pheochromocytoma: Applications for Future Therapies?
por: Korpershoek, Esther, et al.
Publicado: (2012)

The Mitochondrial HSP90 Paralog TRAP1: Structural Dynamics, Interactome, Role in Metabolic Regulation, and Inhibitors
por: Joshi, Abhinav, et al.
Publicado: (2022)

STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma
por: Heske, Christine M., et al.
Publicado: (2016)

Heat Shock Protein 90 and Role of Its Chemical Inhibitors in Treatment of Hematologic Malignancies
por: Ho, Ngoc, et al.
Publicado: (2012)

The XIth International Online Symposium on Heat Shock Proteins in Biology and Medicine: Organizers: Stuart K. Calderwood, Elizabeth Repasky & Len Neckers October 27-29, 2021 IN MEMORIAM: Claudina Rodrigues-Pousada (1941–2021)
por: Calderwood, Stuart K., et al.
Publicado: (2022)

Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition
por: Xu, W, et al.
Publicado: (2007)

Heat Shock Protein 90 (Hsp90) Expression and Breast Cancer
por: Zagouri, Flora, et al.
Publicado: (2012)

Antibodies to Heat Shock Proteins 90α and 90β in Psoriasis
por: Damasiewicz-Bodzek, Aleksandra, et al.
Publicado: (2020)

Personalized Management of Pheochromocytoma and Paraganglioma
por: Nölting, Svenja, et al.
Publicado: (2021)

Heat shock protein 90 in neurodegenerative diseases
por: Luo, Wenjie, et al.
Publicado: (2010)

Heat Shock Protein 90 in Alzheimer's Disease
por: Ou, Jiang-Rong, et al.
Publicado: (2014)

Heat shock protein 90 inhibition in the endothelium
por: Barabutis, Nektarios
Publicado: (2023)

PSAT089 Lack of Effect of Metformin in Murine Pheochromocytoma Model
por: Ghayee, Hans K, et al.
Publicado: (2022)

Postoperative Management in Patients with Pheochromocytoma and Paraganglioma
por: Mamilla, Divya, et al.
Publicado: (2019)

Clinical Significance of Circulating Serum Cellular Heat Shock Protein 90 (HSP90) Level in Patients with Cutaneous Malignant Melanoma
por: Tas, Faruk, et al.
Publicado: (2017)

Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer
por: Cheng, Qing, et al.
Publicado: (2012)

Proteasome inhibition disrupts the metabolism of fumarate hydratase- deficient tumors by downregulating p62 and c-Myc
por: Sourbier, Carole, et al.
Publicado: (2019)

Potential role of heat shock protein 90 (Hsp90) in HIV uncoating
por: Joshi, Pheroze, et al.
Publicado: (2011)

Heat Shock Protein 90 (HSP90) and Her2 in Adenocarcinomas of the Esophagus
por: Slotta-Huspenina, Julia, et al.
Publicado: (2014)

Heat shock protein 90 promotes RNA helicase DDX5 accumulation and exacerbates hepatocellular carcinoma by inhibiting autophagy
por: Zhang, Ting, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kiod1q2hbciu11psda91viqs1v